Investigating Dead Space and Inhaled Nitric Oxide in Children with Acute Respiratory Distress Syndrome
Official title: Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
Run by Children's Hospital Los Angeles · NCT06690801 · Data updated 2026-11-12
This study is testing if a specific marker can help predict the risk of death in children with acute respiratory distress syndrome and see how well inhaled nitric oxide treatment works for them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Years to 21 Years |
| Sex | All |
| Enrollment | 1260 (estimated) |
| Sponsor | Children's Hospital Los Angeles Academic / other |
| Locations | 10 sites (Los Angeles, California and 9 other locations) |
| Status | Recruiting |
| Started | October 3, 2024 |
| Main results expected | December 1, 2028 |
| Study ends | February 1, 2029 |
| Registry record updated | November 15, 2024 |
| Trial ID | NCT06690801 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include children aged over 37 weeks corrected gestational age to 21 years who are mechanically ventilated and meet the criteria for moderate to severe pediatric ARDS.
✕Probably not a fit
Patients receiving non-conventional invasive mechanical ventilation or those not meeting the ARDS criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the association between a specific marker of dead space (AVDSf) and mortality risk in pediatric patients with acute respiratory distress syndrome (ARDS). It will also explore whether AVDSf can indicate variability in the treatment effects of inhaled nitric oxide (iNO) therapy. The study will involve 1260 mechanically ventilated children, with a subgroup of 450 children providing longitudinal blood samples to assess microvascular dysfunction. The goal is to enhance risk stratification and treatment personalization for children suffering from ARDS.
Why it matters
Potential benefit: If successful, this study could improve risk assessment and treatment strategies for children with acute respiratory distress syndrome.
How similar studies have gone: While the approach of using AVDSf as a marker in ARDS is innovative, similar studies have shown promise in understanding treatment effects in respiratory conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>37 weeks corrected gestational age to 21 years, including adults lacking the capacity to consent. * Within 72 hours of the start of invasive mechanical ventilation and meet the criteria for pediatric ARDS (new infiltrate on chest imaging and a known ARDS risk factor within 7 days of the onset of hypoxemia) and either meet criteria for moderate or severe pediatric ARDS between 4-72 hours of IMV (OI ≥ 8 or OSI ≥ 7.5) OR have an OI ≥ 20 or an OSI ≥ 14 x 15 minutes between 0-4 hours of IMV. * Subgroup of children eligible for longituduinal Blood Collection: Children with severe PARDS (OI ≥ 16 or an OSI ≥ 12 between 4-72 hours of IMV) or those with an OI ≥ 20 or an OSI ≥ 14 for 15 minutes between 0-4 hours of IMV will be eligible for collection of longitudinal plasma samples. Exclusion Criteria: * Non-conventional invasive mechanical ventilation (i.e. High Frequency Oscillatory Ventilation, Airway Pressure Release Ventilation) at the time of ICU admission * ECMO or iNO (or other inhaled pulmonary vasodilator therapy) at the time of ICU admission * Significant lower airways obstruction (examination of ventilator and capnography waveforms by site study or medical team) * Air leak \>20% (endotracheal tube, tracheostomy tube, or thoracostomy tube) * Home Invasive Mechanical Ventilation * Cyanotic Congenital Heart Disease * Previous enrollment in the DiNO study * Do not resuscitate order at the time of pediatric ARDS diagnosis. * Blood gas not obtained prior to initiation of ECMO, iNO, or non-conventional ventilation.
Where it's running
-
Children's Hospital Los Angeles
Los Angeles, California, United States Recruiting -
Children's Hospital Colorado
Denver, Colorado, United States Not yet recruiting -
Boston Children's Hospital
Boston, Massachusetts, United States Not yet recruiting -
University of Michigan / CS Mott Children's Hospital
Ann Arbor, Michigan, United States Active not recruiting -
University of Nebraska Medical Center / Children's Hospital and Medical Center
Omaha, Nebraska, United States Not yet recruiting -
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States Not yet recruiting
Show 4 more locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States Not yet recruiting -
Texas Children's Hospital Baylor College of Medicine
Houston, Texas, United States Not yet recruiting -
American Family Children's Hospital / University of Wisconsin-Madison
Madison, Wisconsin, United States Not yet recruiting -
Children's Hospital of Wisconsin / Medical College of Wisconsin
Milwaukee, Wisconsin, United States Not yet recruiting
Study contacts
- Principal investigator: Anoopindar M Bhalla, MD — Children's Hospital Los Angeles
- Study coordinator: Jeni Kwok
- Email: dinostudy@chla.usc.edu
- Phone: 3233617939
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Full-Course ECMO Pathway for Moderate-to-Severe ARDS
This study tests a standardized, full-course ECMO management pathway to see if it improves care for adults with moderate-to-severe ARDS treated with VV-ECMO in real-world Chinese centers.
-
Height measurement methods to guide ventilator settings in ARDS
We’re testing whether more precise height measurements change how researchers set lung-protective tidal volumes in adults with ARDS who are on a ventilator.
-
Corticosteroids for a hyperinflammatory state in critical illness
This trial tests whether methylprednisolone helps improve organ function and survival in adults with sepsis or ARDS who show a hyperinflammatory profile.
-
Right‑heart function and heart–lung interaction during ARDS with mechanical ventilation
This project will follow adults with ARDS on mechanical ventilation to see how positive‑pressure breathing affects the right heart over time and how that relates to circulation.
-
Umbilical‑cord mesenchymal stem cell and secretome therapy for severe ARDS
This trial tests whether IV umbilical‑cord mesenchymal stem cells, alone or with secretome, help adults with severe ARDS recover lung function and reduce inflammation.
-
Human umbilical cord mesenchymal stem cell injection for moderate to severe ARDS
This will test whether a single injection of human umbilical cord mesenchymal stem cells can help adults with moderate to severe ARDS that hasn't improved after standard treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.